FDMT

In October 2025, the company secured an equity investment from the Cystic Fibrosis Foundation. In November 2025, executive changes and concerns over trial data led to a stock decline. In January 2026, Barclays initiated coverage with an "overweight" rating. In March 2026, the company reported full-year 2025 financial results, while Jefferies cut its price target and RBC Capital raised its target. In April 2026, a Janus Henderson filing disclosed a stake in the company, leading to a stock gain, and the company disclosed RSUs granted to new hires. In May 2026, 4D Molecular Therapeutics reported its Q1 2026 results, with a net loss, and Wall Street Zen downgraded the stock.